Company Overview: Catalyst Biosciences

Industry News

6 Jul

Financial Milestone Achieved in Catalyst’s Subcutaneous Factor IX Program

SOUTH SAN FRANCISCO, Calif., July 06, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that it has achieved a financial milestone under its collaboration with ISU Abxis. In June of 2017, the first patient...

Read more

28 Jun

Catalyst Biosciences’ Factor IX Granted Orphan Drug Designation in Europe

SOUTH SAN FRANCISCO, Calif., June 28, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that the European Commission has granted orphan medicinal product designation to CB 2679d/ISU304, a clinical stage drug candidate for hemophilia B....

Read more

26 Jun

Catalyst Biosciences Announces Achievement of Stable Normal Factor IX Blood Levels in a Preclinical Subcutaneous Dosing Model

— Data support ongoing clinical trial in individuals with hemophilia B — — Data to be presented at ISTH oral session Future Biotherapeutics for Hemophilia A and B — SOUTH SAN FRANCISCO, Calif., June 26, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel...

Read more

14 Jun

Catalyst Biosciences and ISU Abxis Complete Dosing of First Patient Cohort in Hemophilia B Clinical Trial

SOUTH SAN FRANCISCO, Calif. and SEOUL, South Korea, June 14, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, and ISU Abxis Co Ltd. (086890.KQ) a commercial-stage biopharmaceutical company and Catalyst’s collaborator in the development of its...

Read more

31 May

Catalyst Biosciences’ Factor IX Recommended for Orphan Drug Designation in Europe

SOUTH SAN FRANCISCO, Calif., May 31, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that the European Medicines Agency (EMA) Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending orphan medicinal...

Read more

7 Apr

Catalyst Biosciences Announces Pricing of $18 Million Underwritten Public Offering

SOUTH SAN FRANCISCO, Calif., April 07, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced the pricing of an underwritten public offering of units for gross proceeds of $18 million, prior to deducting underwriting discounts...

Read more

28 Mar

Catalyst Biosciences Announces IND Approval in South Korea for Next-Generation Subcutaneous Factor IX Program

SOUTH SAN FRANCISCO, Calif., March 28, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that the Korean Ministry of Food and Drug Safety (MFDS) approved the Investigational New Drug Application (IND) for CB 2679d/ISU304....

Read more

16 Feb

Catalyst Biosciences Announces Promotion of Andrew Hetherington to SVP of Technical Operations

SOUTH SAN FRANCISCO, Calif., Feb. 16, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc., (CBIO) a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, today announced that Andrew Hetherington has been promoted to Senior Vice President of Technical Operations. Mr. Hetherington joined Catalyst in September 2015...

Read more

14 Feb

Catalyst Biosciences Highlights Hemophilia Clinical Development Plans at the 19th Annual BIO CEO & Investor Conference

SOUTH SAN FRANCISCO, Calif., Feb. 14, 2017 (GLOBE NEWSWIRE) — Catalyst Biosciences, Inc. (CBIO), a clinical-stage biopharmaceutical company focused on developing novel medicines to address hematology indications, provided an update on its clinical development plans for its next-generation Factor VIIa and Factor IX candidates and reiterated its intention to...

Read more

Page 1 of 212

Enter your email address to receive notifications of new posts by email.

Latest Tweets

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address